High expression of PFTK1 in cancer cells predicts poor prognosis in colorectal cancer

Mao,Youjun; Jia,Yuqing; Zhu,Huijun; Wang,Wei; Jin,Qin; Huang,Fang; Zhang,Shu; Li,Xiaoqiang

doi:10.3892/mmr.2017.6560

High expression of PFTK1 in cancer cells predicts poor prognosis in colorectal cancer

Authors:
- Youjun Mao
- Yuqing Jia
- Huijun Zhu
- Wei Wang
- Qin Jin
- Fang Huang
- Shu Zhang
- Xiaoqiang Li
View Affiliations

Affiliations: Department of Vascular Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China, Department of General Surgery, Friendliness Hospital, Yangzhou, Jiangsu 225009, P.R. China, Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: May 10, 2017 https://doi.org/10.3892/mmr.2017.6560
Pages: 224-230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The serine/threonine-protein kinase PFTAIRE 1 (PFTK1) is a member of the cyclin‑dependent kinase family that is highly expressed in several malignant tumors, including hepatocellular carcinoma, esophageal, breast and gastric cancers, and glioma. It contributes to tumor progression and influences tumor prognosis. However, the expression and clinicopathological significance of PFTK1 in human colorectal cancer (CRC) remain to be elucidated. The present study aimed to examine the expression of PFTK1 and to evaluate the clinical significance of its expression in human CRC. Reverse transcription‑quantitative polymerase chain reaction was performed on 10 fresh CRC and 10 surrounding normal tissue samples to detect and compare the expression of PFTK1 mRNA in CRC and normal colorectal tissues. Immunohistochemistry was performed on 179 CRC tissue specimens and 47 control samples of normal colorectal lesions to characterize the expression of PFTK1 protein. Kaplan‑Meier overall survival (OS) rate and Cox regression analyses were performed to evaluate the prognosis of patients with CRC. The expression of PFTK1 mRNA in CRC tissues (1.433±0.168) was significantly higher compared with normal tissues (0.853±0.107; t=1.97 ('t' was the value obtained from quantification of the mRNA data, following a paired t‑test), P=0.008). High PFTK1 expression in cancerous cells was detected in 92 of the CRC specimens (51.40%), and high levels of PFTK1 were associated with tumor node metastasis (TNM) stage (P=0.042), tumor classification (P=0.022) and preoperative carcinoembryonic antigen (CEA) level (P<0.001). Kaplan‑Meier OS rate and Cox regression analysis revealed that high PFTK1 expression level (hazard ratio (HR)=1.999; P=0.019) was an independent prognostic factor of CRC patients. The degree of differentiation (HR, 0.368, P=0.003), TNM classification (HR, 2.118, P=0.001) and preoperative CEA level (HR, 2.302, P=0.003) were also predictors of the prognosis of patients with CRC. The present study suggested that PFTK1 may be a potential anticancer target and prognostic marker in patients with CRC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics: CA Cancer. J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Gansler T, Ganz PA, Grant M, Greene FL, Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, et al: Sixty years of CA: A cancer journal for clinicians. CA Cancer J Clin. 60:345–350. 2010. View Article : Google Scholar : PubMed/NCBI
3	Huang CW, Tsai HL, Chen YT, Huang CM, Ma CJ, Lu CY, Kuo CH, Wu DC, Chai CY and Wang JY: The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer. 13:5992013. View Article : Google Scholar : PubMed/NCBI
4	Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1413–1418. 1998. View Article : Google Scholar : PubMed/NCBI
5	Karoui M, Roudot-Thoraval F, Mesli F, Mitry E, Aparicio T, Des Guetz G, Louvet C, Landi B, Tiret E and Sobhani I: Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: Results of a multicentric study. Dis Colon Rectum. 54:930–938. 2011. View Article : Google Scholar : PubMed/NCBI
6	Platell C, Ng S, O'Bichere A and Tebbutt N: Changing management and survival in patients with stage IV colorectal cancer. Dis Colon Rectum. 54:214–219. 2011. View Article : Google Scholar : PubMed/NCBI
7	Kleespies A, Füessl KE, Seeliger H, Eichhorn ME, Müller MH, Rentsch M, Thasler WE, Angele MK, Kreis ME and Jauch KW: Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis. 24:1097–1109. 2009. View Article : Google Scholar : PubMed/NCBI
8	Hollis M, Nair K, Vyas A, Chaturvedi LS, Gambhir S and Vyas D: MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity. World J Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI
9	Juliano R: Movin' on through with Cdc2. Nat Cell Biol. 5:589–590. 2003. View Article : Google Scholar : PubMed/NCBI
10	Manes T, Zheng DQ, Tognin S, Woodard AS, Marchisio PC and Languino LR: Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol. 161:817–826. 2003. View Article : Google Scholar : PubMed/NCBI
11	Miyagaki H, Yamasaki M, Miyata H, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Fujiwara Y, Ishii H, Tanaka F, et al: Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. Br J Cancer. 106:947–954. 2012. View Article : Google Scholar : PubMed/NCBI
12	Pang EY, Bai AH, To KF, Sy SM, Wong NL, Lai PB, Squire JA and Wong N: Identification of PFTAIRE protein kinase 1, a novel cell division cycle-2 related gene, in the motile phenotype of hepatocellular carcinoma cells. Hepatology. 46:436–445. 2007. View Article : Google Scholar : PubMed/NCBI
13	Yang T and Chen JY: Identification and cellular localization of human PFTAIRE1. Gene. 267:165–172. 2001. View Article : Google Scholar : PubMed/NCBI
14	Leung WK, Ching AK, Chan AW, Poon TC, Mian H, Wong AS, To KF and Wong N: A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene. 30:4464–4475. 2011. View Article : Google Scholar : PubMed/NCBI
15	Gu X, Wang Y, Wang H, Ni Q, Zhang C, Zhu J, Huang W, Xu P, Mao G and Yang S: Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer. Med Oncol. 32:1952015. View Article : Google Scholar : PubMed/NCBI
16	Yang L, Zhu J, Huang H, Yang Q, Cai J, Wang Q, Zhu J, Shao M, Xiao J, Cao J, et al: PFTK1 promotes gastric cancer progression by regulating proliferation, migration and invasion. PLoS One. 10:e01404512015. View Article : Google Scholar : PubMed/NCBI
17	Fan S, Zhao C, Zhang L, Dai S, Ren J, Zhang X, Ban N, He X, Yang L, Bao Z, et al: Knockdown of PFTK1 inhibits the migration of glioma cells. J Mol Neurosci. 57:257–264. 2015. View Article : Google Scholar : PubMed/NCBI
18	Dai M, Al-Odaini AA, Fils-Aimé N, Villatoro MA, Guo J, Arakelian A, Rabbani SA, Ali S and Lebrun JJ: Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Res. 15:R492013. View Article : Google Scholar : PubMed/NCBI
19	Novak J and Fabian P: Comments on the TNM classification of malignant tumours-7th edition. Klin Onkol. 24:149–150. 2011.(In Czech). PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Sun R, Wang X, Zhu H, Mei H, Wang W, Zhang S and Huang J: Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues. Oncotarget. 5:12398–12409. 2014. View Article : Google Scholar : PubMed/NCBI
22	Huang J, Zhang X, Tang Q, Zhang F, Li Y, Feng Z and Zhu J: Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol. 64:343–348. 2011. View Article : Google Scholar : PubMed/NCBI
23	Poomsawat S, Buajeeb W, Khovidhunkit SO and Punyasingh J: Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions. J Oral Pathol Med. 39:793–799. 2010. View Article : Google Scholar : PubMed/NCBI
24	Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, et al: Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res. 11:R122009. View Article : Google Scholar : PubMed/NCBI
25	Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, Torikoshi Y, Tanaka S, Yoshida T, Ishihara H and Noguchi S: Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol. 19:68–72. 2008. View Article : Google Scholar : PubMed/NCBI
26	Hansel DE, Dhara S, Huang RC, Ashfaq R, Deasel M, Shimada Y, Bernstein HS, Harmon J, Brock M, Forastiere A, et al: CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol. 29:390–399. 2005. View Article : Google Scholar : PubMed/NCBI
27	Semczuk A and Jakowicki JA: Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis. Cancer Lett. 203:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
28	Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, et al: Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene. 21:2476–2483. 2002. View Article : Google Scholar : PubMed/NCBI
29	Marone M, Scambia G, Giannitelli C, Ferrandina G, Masciullo V, Bellacosa A, Benedetti-Panici P and Mancuso S: Analysis of cyclin E and CDK2 in ovarian cancer: Gene amplification and RNA overexpression. Int J Cancer. 75:34–39. 1998. View Article : Google Scholar : PubMed/NCBI
30	Mihara M, Shintani S, Nakahara Y, Kiyota A, Ueyama Y, Matsumura T and Wong DT: Overexpression of CDK2 is a prognostic indicator of oral cancer progression. Jpn J Cancer Res. 92:352–360. 2001. View Article : Google Scholar : PubMed/NCBI
31	Yue W, Zhao X, Zhang L, Xu S, Liu Z, Ma L, Jia W, Qian Z, Zhang C, Wang Y and Yang X: Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis. Clin Lung Cancer. 12:43–50. 2011. View Article : Google Scholar : PubMed/NCBI
32	Yang HJ, Wang L, Wang M, Ma SP, Cheng BF, Li ZC and Feng ZW: Serine/threonine-protein kinase PFTK1 modulates oligodendrocyte differentiation via PI3K/AKT pathway. J Mol Neurosci. 55:977–984. 2015. View Article : Google Scholar : PubMed/NCBI
33	Mullen AR and DeBerardinis RJ: Genetically-defined metabolic reprogramming in cancer. Trends Endocrinol Metab. 23:552–559. 2012. View Article : Google Scholar : PubMed/NCBI